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A large number of anti–HIV-1 antibodies targeting the CD4-binding
site (CD4bs) on the envelope glycoprotein gp120 have recently
been reported. These antibodies, typiﬁed by VRC01, are remark-
able for both their breadth and their potency. Crystal structures
have revealed a common mode of binding for several of these
antibodies; however, the precise relationship among CD4bs anti-
bodies remains to be deﬁned. Here we analyze existing structural
and sequence data, propose a set of signature features for potent
VRC01-like (PVL) antibodies, and verify the importance of these
features by mutagenesis. The signature features explain why
PVL antibodies derive from a single germ-line human VH gene
segment and why certain gp120 sequences are associated with
antibody resistance. Our results bear on vaccine development
and structure-based design to improve the potency and breadth
of anti-CD4bs antibodies.
analysis | selection
Understanding the humoral response against HIV-1 is criticalfor developing new approaches to preventing HIV-1 infection.
Much effort has been devoted to understanding why HIV effec-
tively evades most antibodies (Abs). Accepted explanations include
rapid mutation of the two glycoproteins that comprise the en-
velope spike, gp120 and gp41, and structural features that enable
the spike to hide conserved epitopes from Abs. These structural
features include a shield of host-derived carbohydrates (1),
conformational masking (2), steric occlusion (3), protecting
conserved regions at interfaces by oligomerization (4–6), and the
presence of highly variable ﬂexible loops that shield conserved
epitopes (4, 7). The small number and low density of envelope
spikes on HIV virions may also contribute to HIV’s ability to
evade Abs by preventing most IgGs from binding simultaneously
with both Fabs (8, 9). Combined with HIV’s ability to rapidly
mutate, these features of the HIV spike make it difﬁcult for the
host to develop antibodies with high levels of breadth and potency.
Although strain-speciﬁc Abs are more common, a subset of
HIV-infected individuals develops broadly neutralizing Abs
(bNAbs), i.e., Abs that neutralize many viral strains, and this
happens only several years after infection (10, 11). Until recently,
very few (e.g., 4E10, 2F5, 2G12, and b12) monoclonal human
Abs with broadly neutralizing activity had been isolated (12–15).
However, with the advent of new single-cell cloning techniques
(16, 17), the number of promising bNAbs has been expanded
greatly to include quaternary-speciﬁc Abs, whose epitopes in-
volve gp120 glycosylation and the gp120 variable loops (18, 19),
and a series of Abs that recognize the CD4-binding site (CD4bs)
on gp120 [e.g., VRC Abs (20, 21), HJ16 (22), and highly active
agonistic anti-CD4bs (HAAD) Abs (23)]. In addition, sequences
of isolated heavy and light chains related to these Abs were
obtained by deep sequencing methods (21). Some of the new
CD4bs Abs, e.g., VRC01, NIH45–46, 3BNC117, VRC-PG04,
and VRC-CH31, are remarkable for their breadth (neutralizing
∼90% of strains) and the relative inability of HIV to escape these
Abs by altering its glycan shield (20, 21, 23).
Interestingly, despite being isolated from different donors, the
HAAD and VRC01-like CD4bs Abs arose from two closely re-
lated germ-line IgVH genes (VH1-2 and VH1-46) (23), which
underwent extensive somatic hypermutation (65–91 somatic mu-
tations within 288 nucleotides) (21) to produce Abs with divergent
sequences, including some related by <50% amino acid identity.
Structures of the Fabs of VRC01-like Abs have been solved as
complexes with HIV gp120 (21, 24, 25), revealing that these Abs
all bind to gp120 by mimicking CD4; speciﬁcally, VH chain residue
Arg71 (Arg71VH) forms a favorable ionic interaction with
Asp368gp120 to mimic Arg59CD4, and backbone atoms in the VH
domain C′′ strand form direct and water-mediated hydrogen
bonds with the CD4-binding loop in gp120. Here we present
analyses of the available structural and sequence data for the
CD4bs Abs and propose a classiﬁcation system that can be used
to predict their binding and neutralization potencies and that
rationalizes their origin from speciﬁc germ-line precursors. Site-
directed mutagenesis is used to verify these predictions. This
information should assist in vaccine development as well as in
efforts to improve these antibodies by structure-based design.
Results
Sequence Signatures of Potent CD4bs Abs. The starting point of
our analyses is the correlation between neutralization potency
and the length of two of the light-chain CDR loops. The rela-
tively small CDRL1 of VRC01, which has a two-residue deletion
relative to its germ-line precursor, was previously correlated with
increased neutralization potency (25). We noticed that sequences
of VRC01, NIH45–46, and VRC-PG04 revealed a more striking
correlation for the length of CDRL3, which is only 5 residues
in these Abs (Fig. 1A). Examination of the large Abysis database
for human Ab sequences (http://www.bioinf.org.uk/abs/) showed
that only ∼1% of VL domains have a CDRL3 length of 5 aa,
compared with more typical 9- to 11-residue lengths (Fig. 1B).
The structure of the NIH45–46–gp120 complex (24) suggests
that the 5-residue length may be because there is not enough
space for a longer CDRL3: The end of the NIH45–46 CDRL3
(residues 91LC and 96LC) directly contacts the side chain of
Trp100BHC to stabilize the Ab VH-VL interface and the
CDRL3 tip is near gp120 loop D residues 279gp120 and 280gp120
(Cα 91LC–Cα 279gp120 distance of 6.9 Å). Larger CDRL3 loops
would place critical side chains at the tip of CDRL3 in different
locations and thus would not be able to interact with gp120 in the
same manner. In Abs with longer CDRL3s, the tip of CDRL3
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interacts with Trp47HC, a highly conserved residue (found in 63
of 69 germ-line VH gene segments) (26) that plays a similar role
to that of Trp100BHC in the Abs with 5-residue CDRL3s to
stabilize the VH-VL interface. This analysis of CDRL3 length
suggests that potent anti-CD4bs Abs such as 8ANC131,
8ANC134, 1B2530, and 1NC9 (23), which have 9- or 11-residue
CDRL3s (Table 1), are unlikely to bind gp120 in the same
manner as the VRC01-like antibodies. In addition, this group
of anti-CD4bs Abs lacks other sequence features found in
VRC01, NIH45–46, and VRC-PG04: speciﬁcally, Trp50HC,
Asn58HC, and Trp100BHC (23) (Fig. S1 A and B).
V-domain alignments (Fig. 2 A and B) reveal the following
sequence characteristics of the most potent of the VRC01-like
Abs: complete conservation of heavy-chain Arg71HC, Trp50HC,
Asn58HC, and Trp100BHC and light-chain Glu96LC and Trp67LC/
Phe67LC and a CDRL3 length of exactly 5 aa. [Kabat numbering
is used herein for antibody sequences. Residues that have dif-
ferent Kabat numbering in different potent VRC01-like (PVL)
Abs are named by their VRC01 numbering; in particular,
Trp100BHC, although at a ﬁxed location relative to the C-terminal
end of CDRH3, has a different numbering in each PVL Ab:
100B in VRC01, 100D in VRC-PG04, and 100F in NIH45–46.
In the NIH45–46/gp120 structure, Protein Data Bank (PDB)
code 3U7Y, this residue is numbered 102.] The heavy-chain
sequence characteristics are found in CD4bs Abs that descended
from the VH1-2 germ line, but not from the VH1-46 germ line
(23). Analysis of the per residue variability of VH1-2*02–derived
Abs indicates that the conservation of Trp50HC and Asn58HC is
unlikely to be coincidental (Table 2 and Fig. S2).
The roles that conserved residues play in the VH domain
structure and in binding to the CD4bs on gp120 are shown
schematically in Fig. 3 and in stereo in Fig. S3. Fig. 3 and Fig. S3
are based on interactions present in the gp120 complexes of
VRC01, NIH45–46, and VRC-PG04 (21, 24, 25). The side chains
of Trp50HC, Trp100BHC, and Trp47HC form an unusual propeller-
like arrangement on the surface of the VH domain. (Although
Trp47HC participates in the “propeller,” we do not consider it to
be a signature residue of potent CD4bs Abs because it is com-
monly found in VH domains) (26). The main interactions of
the characteristic VH domain residues with gp120 are as follows:
Trp50HC, indole N-H hydrogen bonds with the side-chain oxygen
of Asn280gp120; Asn58HC, side chain N-H hydrogen bonds with
the backbone carbonyl of Arg456gp120; Arg71HC, side chain hy-
drogen bonds/salt bridges with the side chain of Asp368gp120; and
Trp100BHC, indole N-H hydrogen bonds with the side-chain
oxygen of Asn/Asp279gp120. Trp100BHC also buries 85 Å
2 of sur-
face area at the VH/VL interface—contacting residues Tyr91LC
and Glu96LC.
In the light chains, the side chain of Glu96LC forms a hydrogen
bond with the backbone nitrogen of Gly459gp120 and/or the side
chain of Asn280gp120. The conservation of Trp67LC/Phe67LC is
surprising as this position is distant from gp120 in the available
crystal structures. However, this hydrophobic residue may in-
teract with a portion of the glycan attached to Asn276gp120 that
was disordered in these structures; this potential N-linked gly-
cosylation site is present in ∼90% of HIV-1 strains.
For those interactions that depend on speciﬁc gp120 side
chains, the degree of conservation of the relevant gp120 residues
is 96.4% for Asn/Asp279gp120, 96.4% for Asn280gp120, and 99.7%
for Asp368gp120 (based on the 2010 ﬁltered web alignment of
2,869 HIV-1 sequences in the Los Alamos HIV database: http://
www.hiv.lanl.gov/). Arg456gp120, which is involved in a main-chain
hydrogen bond with the side chain of Asn58HC, is also highly
conserved (95.0%).
PVL Class of CD4bs Abs. Individual CD4bs Abs bear a variety
of names that do not generally describe their properties (20, 21,
23). For this reason, we propose a nomenclature to describe
the class of highly potent CD4bs Abs that include the following
common features: conservation of Arg71HC, Trp50HC, Asn58HC,
Trp100BHC, Glu96LC, and Trp67LC/Phe67LC; exactly 5 aa in
CDRL1; and neutralization of >75% of HIV strains with IC50s
(the concentrations at which half-maximal neutralization is
achieved in an in vitro neutralization assay) <50 μg/mL (it should
be noted that some Abs cannot be classiﬁed with certainty
Fig. 1. Length distributions of human CDRL1 and CDRL3. (A) Length
distributions of human CDRL1 and CDRL3 in the PDB. The red bars all rep-
resent CD4bs Ab structures. (B) Distribution of CDRL3 lengths of human Abs.
The Abysis database (http://www.bioinf.org.uk/abysis/index.html) was queried
for CDRL3 lengths. CDRL3 was deﬁned according to the Chothia deﬁnition in
the Abysis server.
Table 1. High potency, broadly neutralizing CD4bs Abs
Origin VH CDRH3 length VL κ/λ CDRL1 length CDRL3 length
VRC01, NIH45–46 Donor 45 1-2 12, 16 K3-11 9 5
VRC-PG04, VRC-PG04b Donor 74 1-2 14 K3-20 9 5
VRC-CH30–VRC-CH34 Donor 0219 1-2 13 K1-33 11 5
3BNC117, 3BNC60, 3BNC62,
3BNC95, 3BNC176
Patient 3 1-2 10 K1-33 7 5
12A12 Patient 12 1-2 13 K1-33 11 5
8ANC131, 8ANC134 Patient 8 1-46 16 K3-11 10 9
1B2530 Patient 1 1-46 16 L1-47 13 11
1NC9 Patient 1 1-46 19 L1-47 13 11
8ANC195 Patient 8 1-69 20 K1-5 12 9
Antibodies are described in refs. 20, 21, and 23. Germ-line V segment genes and selected CDR lengths (Chothia deﬁnition) are given.
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because of the large margin of error for the breadth of Abs
evaluated only on small viral panels). We refer to Abs with
these characteristics as PVL Abs, for “Potent VRC01-Like”
Abs, reﬂecting the ﬁrst of this class to be isolated (20). PVL
Abs would include subsequently described CD4bs Abs such as
NIH45–46, 3BNC117, 12A12, VRC-PG04, VRC-CH31, and
a number of related variants (21, 23) (Table 1 and Fig. 2).
We refer to CD4bs Abs that include some, but not all, of the
signature residues of PVL Abs and neutralize 10–75% of HIV
strains with IC50s < 50 μg/mL as “almost PVL” Abs. This cate-
gory includes VRC03, 3BNC55, 3BNC91, 3BNC104, 3BNC89,
and 12A21 (Table S1). VRC03 is unusual with respect to its
neutralization breadth because when the VRC03 heavy chain is
paired with its cognate light chain, it does not neutralize well
enough to belong to the PVL class of Abs (nor does it contain
all of the signature sequence characteristics); however, when
the VRC03 heavy chain is paired with the VRC01 light chain, the
chimeric Ab exhibits broader neutralization (21). Although the
heavy and light chains of members of the PVL Ab class are often
interchangeable (21), the VRC03 example illustrates the difﬁculty
of using potency to categorize Abs identiﬁed by deep sequencing
(21) because the recombinant Abs used in neutralization assays
may not have been paired with their physiological light chains.
3BNC55 represents an interesting example of an almost PVL
Ab that has less breadth than the PVL Abs, but nonetheless neu-
tralizes a viral strain, T250-4, that is resistant to PVL Abs (23). The
T250-4 gp120 sequence includes Pro459gp120 (a substitution from
Gly459gp120), which lacks a backbone NH group to hydrogen bond
with Glu96LC in the Ab light chain (Fig. 3). The replacement of
Trp100BHC with Cys100BHC in 3BNC55 and other defective PVL
A
B
Fig. 2. Sequence alignments of PVL Abs. (A) Alignment of the heavy chains of PVL Abs, their less potent relatives, and their germ-line precursor. The less
potent Abs are shaded in gray. PVL characteristic residues are highlighted in purple. [Note that W100B was not consistently aligned in previous lists of CD4bs
Ab sequences (21, 23)]. Antibodies VRC-H5, VRC-H12, and VRC–H15 are heavy chains isolated by deep sequencing of donor 74 paired with the VRC-PG04 light
chain. *VRC03 has several notable differences from other VRC01-like antibodies: Trp100BHC is replaced by Phe, there is a 7-aa insertion in framework region 3,
there is a disulﬁde bond within CDRH3 (in contrast to the CDRH1–CDRH3 disulﬁde found in VRC01 and NIH45–46), it is the only isolated VRC01-like antibody
with Trp54HC, and the VRC03 light chain lacks a hydrophobic residue at position 67, instead retaining the germ-line Ser residue at position 67. (B) Alignment
of the light chains of PVL Abs, their less potent relatives, and their germ-line precursors. The less potent Abs are shaded in gray. PVL characteristic residues are
highlighted in purple; glycosylation sites are highlighted in green.
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Abs may represent an adaptation of the Ab to allow Glu96LC,
which normally hydrogen bonds with the Gly459gp120 back-
bone, to move into the space otherwise occupied by the bulky
Trp100BHC side chain and perhaps hydrogen bond with the side
chain of Asn280gp120. Thus, production of less effective almost
PVL Abs such as 3BNC55 may be selected in HIV-infected pa-
tients in response to evolution of viruses such as T250-4 that
are resistant to PVL Abs. A similar in vivo selection scenario has
been proposed for VRC03 and VRC06 (27).
Some of the CD4bs Abs with 3BNCx names (where x is
a number) (23) fall into a category we refer to as “defective
PVL” Abs, deﬁned as Abs that lack some PVL signature residues
and that neutralize <10% of HIV strains with IC50s < 50 μg/mL.
These Abs show some common sequence patterns: In 12 of
15 defective PVL 3BNCx Abs, Trp100BHC is replaced by Cys,
and in 13 of the 15, Asn58HC is replaced by Ser (Fig. 2A). Of the
defective 3BNCx Abs, the only one to include both Trp100BHC
and Asn58HC is 3BNC104, which comes closest to neutralizing as
well as the PVL Abs (23).
Germ-Line PVL Binding to HIV—Effects of Mutating Critical Residues.
All of the PVL Abs are derived from a single germ-line VH gene
segment, IGHV1-2, and from the 02 allele of this gene segment
(IGHV1-2*02) (20, 21, 23). One explanation for this ﬁnding
is that the signature PVL residues identiﬁed above need to be
present in the initial rearranged germ-line B-cell receptor Ab.
Testing this hypothesis is difﬁcult because germ-line versions of
PVLs and other anti-gp120 bNAbs have been reported to show
little or no binding to puriﬁed HIV envelope proteins (23, 25,
28). However, these binding assays are often conducted with
low-micromolar protein concentrations. In addition, because the
exact sequence of the HIV envelope protein that originally stim-
ulated the B cell expressing the germ-line B-cell receptor cannot
be determined, a lack of detectable binding to one or even several
gp120s does not rule out the possibility of germ-line Ab binding
to the original virus.
Half–germ-line versions of VRC01 were reported to retain
some binding and neutralization activities (25), providing a po-
tential method to evaluate germ-line Ab interactions with gp120.
Fig. 3. (Left) Schematic illustration of the common interactions of PVL Abs (magenta and blue-gray) with gp120 (black, left) and CD4 (magenta) with gp120
(black, right). Inset shows the approximate viewpoint of the diagram. (Right) The degree of conservation of critical gp120 residues in HIV-1 strains is
highlighted. A stereo version of the Left is shown in Fig. S3.
Table 2. PVL residues conserved from the germ-line VH1-2*02
gene segment listed in order of improbability of conservation
based on variability in a set of 253 (non-PVL) VH1-2*02–derived
Abs
Residue P value
Trp50HC 0.00005*
Asn58HC 0.001*
Gln6HC
† 0.07
Arg71HC 0.27
*Likelihood < 0.05.
†Residue does not contact gp120. The most common VH1-2*02 mutation
of this residue is to Glu; nonoccurrence of this mutation may be due to an
unfavorable effect on gp120 binding of adding a negative charge to the
VH domain.
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For our experiments, we paired a germ-line 3BNC60 heavy chain
with the mature 3BNC60 light chain to provide sufﬁcient binding
strength for comparisons with mutated germ-line heavy chains.
An SPR-based binding assay demonstrated detectable binding of
the germ-line heavy-chain/mature light-chain IgG to immobilized
gp140 trimers (Fig. 4). We then compared the binding of germ-
line heavy-chain IgGs with substitutions in the four signature
heavy-chain residues (W50S, N58S, R71T, and W100BS) (again
paired with the mature 3BNC60 light chain) (Fig. 4 and Fig. S4).
The W50S, R71T, and W100BS mutants showed little or no
gp140 binding, and the N58S mutation diminished binding by
∼20-fold, consistent with the corresponding PVL characteristic
residues playing key roles in recognition of the HIV-1 envelope
spike by the germ-line PVL B-cell receptor (Table 3).
Sequence Patterns That Select the Germ-Line Parents of PVL Abs.
A requirement for the PVL signature residues to be present
in the germ-line heavy chain greatly restricts the possible parent
VH gene segments of PVL Abs to those that include Trp50HC,
Arg71HC, and Asn58HC (Trp100BHC is encoded outside the VH
gene segment). A requirement for Trp50HC would narrow pos-
sible germ-line VH gene segments to the VH1 and VH7 families
(29), excluding common VH1 gene segments that lack Trp50HC
such as VH1-69, VH1-24, VH1-46, and VH1-f. A requirement
for Arg71HC would eliminate VH7 germ-line segments, as well
as the common VH1 segments VH1-18, VH1-69, VH1-f, and
VH1-24. A requirement for Asn58HC would exclude other VH1
segments: VH1-c, VH1-3, VH1-46, and VH1-8. The only germ-
line VH gene segments that include all of the VRC01 signature
residues are VH1-2, VH1-45, VH1-58, and VH1-68, of which
VH1-68 is a pseudogene (Fig. S5). The rank order of the fre-
quency with which VH1 gene segments are used is VH1-3
(6.2%), VH1-18 (6%), VH1-2 (2.2%), VH1-46 (2%), VH1-69
(1.8%), VH1-8 (0.8%), VH1-f (0.25%), VH1-58 (0.2%), VH1-24
(0.1%), VH1-45 (0.1%), and VH1-c (0.1%) (segments contain-
ing the signature heavy-chain residues of PVL Abs are under-
lined) (30). VH1-2 is >10-fold more common than the next most
frequent germ-line segment containing all PVL signature resi-
dues (VH1-58), thus rationalizing the common germ-line VH
gene segment origin of known PVLs. It may be possible that PVL
Abs can be derived from the VH gene segments VH1-45 and/or
VH1-58; if so, such Abs have yet to be discovered.
The VH1-2 locus has several common alleles. Two alleles,
VH1-2*01 and VH1-2*05, lack Trp50HC and would be unlikely
to generate PVL Abs. The VH1-02*02 allele, however, encodes
Trp50HC; thus the presence of this residue together with Arg71HC
and Asn58HC may be sufﬁcient to explain the use of the VH1-
02*02 gene segment for PVL Abs. Individuals with no alleles
encoding VH1-2 gene segments with Trp50HC may have a reduced
likelihood of successful immunization to produce PVL Abs.
However, if polymorphism at residue 50HC is distributed ran-
domly in the population, only 5.3% of individuals would lack any
VH1-2 allele with Trp50HC (SI Materials and Methods).
Of relevance to efforts to raise PVL Abs in experimental ani-
mals, we asked whether mouse, rat, rabbit, and macaque genomes
include VH gene segments containing these residues. An exam-
ination of mouse, rat, and rabbit VH gene sequences (29) [Im-
MunoGeneTics (IMGT): http://www.imgt.org/IMGTrepertoire/
Proteins/index.php] indicates that none have VH segments that
include the combination of Trp50HC, Arg71HC, and Asn58HC
(Table S2). However, there is a VH1-2*02-like segment in the
macaque genome that possesses all of the PVL characteristic
residues except Asn58HC (31). In addition, the guinea pig ge-
nome contains two germ-line VH genes (GenBank accession nos.
XM_003464985 and XM_003464972) with the PVL Ab charac-
teristic residues; however, it is not clear whether these germ-line
genes are functional because there are no corresponding
sequences of mature guinea pig Abs in GenBank.
The ﬁnal signature PVL residue, Trp100BHC, is encoded either
at the 5′ end of the JH gene segment or at the junction between
the D and JH segments. Only one JH gene segment, IGHJ2*01,
encodes Trp100BHC. IMGT/V-QUEST (version 3.2.24) (32)
assigns the most probable J gene segment used by VRC01,
VRC-PG04, 3BNC117, and 12A12 as IGHJ2*01 (see SI Materials
and Methods for additional analysis). Notably, IGHJ2*01 is the
least frequently used JH segment (<5%) (30), suggesting a selec-
tion for the use of IGHJ2*01 by PVL Abs. Considering that
Trp100BHC is a signature residue of PVL Abs and is critical for
gp140 binding by the half–germ-line Ab (Table 3), we suggest that
a number of these Abs originated from a IGHJ2*01-derived
recombined ancestor that encodes Trp100BHC. Other Abs, such
as VRC03 (which lacks Trp100BHC), do not use IGHJ2*01.
The light chains of PVL Abs derive from a variety of VL gene
segments, suggesting that PVL Abs do not show much restriction
in VL gene use. Unlike the heavy chain, the VL gene segment
region in mature PVL light-chain sequences does not contain
any characteristic residues shared with the germ-line precursors;
the PVL signature light-chain hydrophobic residue (Trp/Phe67LC)
is somatically changed from the germ-line residue Ser (Fig. 2B).
However, in addition to being unusually short, the CDRL3 of PVL
Abs (encoded by the VL-JL join and JL gene segment) includes
a partially conserved consensus sequence: QQYEF (underlined
residues are more conserved; Fig. 2B). The beginning of this
sequence (QQ or QQY) derives from the 3′ end of the germ-line
Fig. 4. Binding to immobilized YU2 gp140 of 3BNC60 IgG, 3BNC60 germ-line
heavy chain/mature light chain (gHC/mLC), and germ-line heavy-chain mutants
paired with mLC. The concentration of injected Ab is indicated in parentheses
after each Ab. The injection period is indicated as a bar at the top.
Table 3. Binding of 3BNC60 Abs with mature, germ-line, or
mutant variable domains to gp140
3BNC60 HC 3BNC60 LC
Apparent gp140 afﬁnity
(Kd values)
Mature Mature <0.1 nM
Germ line Mature 0.5 μM
Germ-line W50S Mature No binding
Germ-line N58S Mature ∼10 μM
Germ-line R71T Mature ∼100 μM
Germ-line W100BS Mature No binding
Germ line Germ line No binding
A surface plasmon resonance-based binding assay was used to evaluate
the interaction of injected Ab with immobilized YU2 gp140. For samples
with no observed binding, Abs were injected at a minimum concentration
of 30 μM. Derived Kd values are apparent afﬁnities that implicitly include
avidity effects due to bivalent binding. Low-afﬁnity interactions did not ﬁt
well to a 1:1 binding model and apparent afﬁnities listed are approximate.
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VL gene segment, whereas the rest is the result of hypermutation
and/or nucleotide addition between the VL and JL gene segments.
Acquisition of Tyr91LC and Glu96LC (the Y and E in the QQYEF
sequence) may represent key steps in the maturation of PVL Abs.
gp120 Sequence Features Correlated with Complete Resistance to
PVLs. To examine the importance of the signature PVL Ab res-
idues to their activity, we analyzed the gp120 sequences of
HIV-1 strains resistant to neutralization by NIH45–46. The
gp120 residue variants associated with resistance were identiﬁed
by three criteria: First, they are contact residues with NIH45–46
(24); second, they are present in NIH45–46-resistant viruses; third,
they do not appear in NIH45–46-sensitive viruses. The critical
positions identiﬁed were 279gp120, 280gp120, 456gp120, 458gp120, and
459gp120; the common (i.e., sensitive) residues at these positions
are Asx, Asn, Arg, Gly, and Gly, respectively. These sites make
signiﬁcant contacts with the characteristic PVL residues (Fig. 3).
Viral strains with variations at these sites are generally neutralized
poorly by all PVL Abs, as expected if substitutions at these posi-
tions interfere with common interactions (Table S3).
To verify the signiﬁcance of gp120 variations at these posi-
tions, we engineered point mutants within the gp160 gene of
HIV-1 strain YU2, created pseudoviruses carrying the mutant
gp160s, and determined the neutralization potencies of the PVL
NIH45–46G54W (24) (as characterized by IC50 values). Mutations
at 279gp120 and 280gp120 rendered the virus resistant to neutral-
ization by NIH45–46G54W, and substitution of 458gp120 diminished
the neutralization potency by >1,500-fold (Fig. 5).
We also examined sequences for HIV envelopes isolated from
donor 45 (from whom VRC01, VRC03, and NIH45–46 were
isolated) (20, 23), including 3 early proviral clones sensitive to
VRC01 and 26 later clones that were insensitive to VRC01,
plus additional Env clones from other individuals with strongly
HIV-1–neutralizing sera (27). Variation at the critical gp120 sites
(279gp120, 280gp120, 456gp120, 458gp120, and 459gp120) correctly pre-
dicted sensitivity to PVL Abs for all 29 gp120 sequences from
donor 45 (Fig. S6). Speciﬁcally, variation at position 279 was
sufﬁcient to explain the sensitivity/resistance characteristics: The
3 early (proviral) clones sensitive to VRC01 encoded Asp279gp120,
whereas none of the 26 VRC01-resistant clones that arose later
encoded either Asp or Asn at position 279 (Glu279gp120 was the
most common residue in this set) (Fig. S6).
For the full set of 100 clones with reported neutralization data
(27), we ﬁnd that VRC01 sensitivity is strongly correlated with
the residue at position 279. In this group of clones, 34 had Asx
at position 279; other common residues were Glu (33 clones)
and Lys (14 clones). Of the 31 well-neutralized viruses (VRC01
IC50 < 10 μg/mL), 26 included the PVL-sensitive pattern
(Asx279gp120, Asn280gp120, Arg456gp120, Gly458gp120, and
Gly459gp120) (average IC50 = 0.83 μg/mL), whereas 5 had the
resistant pattern (other residues at positions 279gp120, 280gp120,
456gp120, 458gp120, and 459gp120). Of the 69 poorly neutralized
viruses (IC50 > 10 μg/mL), 63 had the PVL-resistant pattern, and
6 had the sensitive pattern. Together, the PVL sensitivity pattern
correctly predicted the activity of this class of antibodies against
89 of 100 viruses. In particular, it appears that Asx at 279gp120 has
been strongly selected against in the viral population in these
individuals. Although position 279gp120 is usually predictive, two
Env clones had Lys279gp120, yet were well neutralized by VRC01.
For YU2, we found that the N279Kmutation increased the IC50 for
NIH45–46G54W by >5,000-fold (Fig. 5). Thus, resistance to viruses
encoding Lys279gp120 can be context (i.e., strain) dependent.
The PVL Ab 12A12 neutralizes HIV-1 strains 6540_v4_c1 and
6545_v4_c1, which other PVLs do not. These strains encode
potential PVL-resistant variations Ser280gp120, Ser456gp120, and
Tyr458gp120. The explanation for the ability of 12A12 to neu-
tralize PVL-resistant strains may involve an unusual CDRH3
residue, Leu100DHC, in place of Phe or Tyr at this position. This
substitution may indirectly permit a larger residue to be ac-
commodated at position 458gp120; e.g., Tyr458gp120 could induce
Trp47HC of the antibody to ﬂip into a cavity that exists only with
a smaller side chain such as Leu100DHC in place of Phe or Tyr.
Discussion
Designing an HIV-1 vaccine that provides robust protection
from HIV-1 infection remains a challenge despite many years
of effort. The nature of the problem is most clearly illustrated
by the essentially uniform inability of the immune system to clear
the infection. Despite these difﬁculties, the ﬁnding of broadly
neutralizing sera in a subset of infected individuals (33) provides
a promising starting point for vaccine design. Neutralizing
activity targets a variety of sites on the envelope spike—the
CD4-binding site, the coreceptor-binding site, quaternary sites
involving variable loops and glycosylation sites, and the V3 loop
(16). Cloning, structural, and mechanistic studies have provided
a base of knowledge to design antigens capable of generating
these speciﬁcities. Nevertheless, immunization attempts to date
have not been successful in eliciting strongly neutralizing Abs.
For example, antigens designed to give 2G12-like (34), 4E10-like
(35), or 2F5-like Abs (36) have had limited success, and although
immunogens designed for greater CD4bs recognition showed an
improved ability to elicit CD4bs neutralizing Abs, the potencies
of these Abs were generally limited to the most neutralization-
sensitive (Tier 1) viruses (37). In addition, a gp120 designed
speciﬁcally to focus the immune response to the initial CD4-
binding site on gp120 failed to elicit broadly potent CD4bs Abs
(38), although this designed gp120 was the bait used to isolate
VRC01 (20), a remarkably potent Ab that is the prototype
member of the PVL Abs analyzed in our study.
The requirement or near requirement for PVL Abs to be
derived from the VH1-2 gene segment has several implications.
For testing antigens designed to elicit PVL-like Abs, it is likely
that animals lacking a germ-line gene containing the signature
residues will fail to generate PVL Abs. In particular, the absence
of any germ-line VH segments with the PVL motif in mice or
rabbits indicates that an alternative testing platform would be
preferable. For example, transgenic rodent strains incorporating
some or all of the human Ig locus (39) would be a superior plat-
form for evaluating the potential of gp120 antigens for generation
of this unique class of Abs.
Understanding germ-line PVL Ab binding to gp120 is critical
for immunogen design. Factors working against elicitation of
PVL Abs include the restriction of possible parental germ-line
VH segments, the infrequency of rearranged light-chain genes
Fig. 5. Effects of mutations at critical residues in YU2 gp120 on neutrali-
zation by PVL antibody NIH45–46G54W. IC50 values are the mean of several
independent experiments, one of which is shown on the Left. Although the
IC50s for the G459D YU2 mutant and wild-type YU2 are similar, the G459D
curve is more shallow, resulting from incomplete neutralization at higher
concentrations.
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encoding ﬁve-residue CDRL3 regions, and the high degree of
somatic hypermutation in the mature PVL Abs. With respect to
the CDRL3 length, it is not clear whether PVL Abs originate
as germ-line Abs with ﬁve-residue CDRL3s or whether the short
length results from deletion during somatic mutation, as occurs
for achieving the short length of CDRL1 (25). For choosing the
strain of HIV-1 for a gp120 immunogen, a critical question is
whether the germ-line PVLs bind weakly to gp120s from a wide
variety of strains or whether rare forms of gp120 bind to the
germ-line Abs initiating the maturation process. In light of this
question, one general approach is to modify gp120 antigens
to enhance binding to germ-line or half–germ-line versions
of PVL antibodies, while maintaining contacts with the PVL
signature residues.
The characteristic PVL residues we have identiﬁed suggest
a common pathway for development of potent CD4bs Abs—
beginning with heavy chains derived from VH1-2*02 and (usually)
IGHJ2*01. Although some CD4bs Abs with variations at position
100BHC and/or different germ-line origins are capable of being
strongly neutralizing, we suggest that the PVL class represents
the mostly probable form of broadly neutralizing, highly potent
CD4bs Ab that can develop in humans, as evidenced by their
independent isolation from ﬁve different individuals (20, 21, 23).
Materials and Methods
Sequence Analysis. Protein sequences of antibodies were aligned using the
ClustalW2 multiple-sequence alignment tool at http://www.ebi.ac.uk/Tools/
msa/clustalw2/, followed by manual adjustments based on published struc-
tures of the Abs alone or in complex with gp120. HIV-1 envelope sequences
were aligned on the basis of DNA sequences using the Gene Cutter tool at
http://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html. Multi-
ple-sequence alignments (along with IC50s from neutralization assays when
analyzing envelope sequences) were then read and analyzed to identify
patterns, using a custom Objective-C program.
Analysis of Likelihood of Conservation of Germ-Line Residues. To estimate the
probability of conservation of germ-line residues, we combined a position-
dependent relative rate of mutation (at the protein level) with an estimate
of the amino acid frequency distribution per position expected in a popula-
tion of “fully” hypermutated VH domains. By fully hypermutated, we mean
that additional mutation no longer changes the per residue amino acid
frequencies within the population of Abs. An approximate rate of mutation
of VH1-2*02 gene segment residues was estimated by calculating the fre-
quency of conservation, freqCons(i), for each position i by aligning and ex-
amining a set of 253 VH1-2*02–derived Abs (identiﬁed by IMGT; none of
these are PVL Abs) (29). Fig. S2, which shows variability by residue [i.e., 1 –
freqCons(i)], displays the approximate rate of mutation, which results from
a combination of factors: the probability of nucleotide mutation, the tolerance
of VH positions to mutation, and selection for improved antigen binding.
A distribution of VH amino acid frequencies for fully somatically mutated
VH domains was calculated from a set of 1,461 heavy chains from the
IMGT/3Dstructure database. These sequences include both VH gene diversity
and somatic hypermutation, constrained to maintain VH domain function.
This distribution is denoted as relaxedFreq(i, r), for the frequency of amino
acid r at position i.
We estimate the probability of conservation of germ-line amino acid r at
position i after a degree of hypermutation parameterized by x as
probði; rÞ ¼ ð1− relaxedFreqði; rÞÞ · freqConsðiÞ^x þ relaxedFreqði; rÞ;
where one overall value for x (x = 17.2) was chosen so that the average number
of mutations expected in a mature VH domain matched the average number
of mutations (37.8) seen in the ﬁve PVL Abs considered. For the 253 VH1-2*02
Ab VH regions used to calculate freqCons(i), there were an average of 9.3
residue mutations compared with the germ line. The scaling by x was done to
adjust for the much higher level of somatic hypermutation in the PVL Abs.
For our set of ﬁve independent PVL Abs (each isolated from a different
individual), we chose 3BNC117, 12A12, VRC01, VRC-CH31, and VRC-PG04.
The likelihood estimate for complete conservation of germ-line residue r at
position i in our ﬁve PVL Abs is 28*prob(r, i)^5. This estimate includes
a Bonferroni correction for multiple tests using the number of VH gene
segment residues (n = 28) completely conserved in the set of ﬁve PVL Abs
compared with the germ line. A variety of alternative models were also used
to provide likelihood estimates; although the calculated values differed,
a strong signal for signiﬁcance was found for PVL signature residues Trp50HC
and Asn58HC (Table 2). The conservation of the third signature residue
encoded within the VH domain, Arg71HC, was not as improbable, because
Arg is often found in this position.
Materials. The 3BNC60 germ-line heavy-chain gene and puriﬁed YU2 gp140
trimers were provided by Johannes Scheid (The Rockefeller University).
Mutagenesis. QuikChange mutagenesis was used to generate Ab and gp160
mutants. All gene constructs were veriﬁed by complete sequencing.
Protein Expression and Puriﬁcation. Abs were expressed transiently in a sus-
pension of HEK 293–6E cells (NRC Biotechnology Research Institute, Mon-
tréal, QC, Canada), using 25 kDa linear polyethylenimine (PEI) (Polysciences)
for transfection as described in refs. 24 and 40. Supernatants were passed
over MabSelect SuRe protein A resin (GE Healthcare), eluted using pH 3.0
citrate buffer, and then immediately neutralized. Antibodies tested in neu-
tralization or binding assays were further puriﬁed by size exclusion chro-
matography, using a Superdex 200 or 75 10/300 GL column.
In Vitro Neutralization Assays. A TZM-bl/pseudovirus neutralization assay
was used to evaluate the neutralization potencies of the Abs (41, 42) as
described in ref. 24. Pseudoviruses were generated by cotransfection of HEK
293T cells with an Env expression plasmid and a replication-defective back-
bone plasmid. Neutralization was determined by measuring the reduction in
luciferase reporter gene expression in the presence of Ab NIH45–46G54W
following a single round of pseudovirus infection in TZM-bl cells. Nonlinear
regression analysis was used to calculate the concentrations at which half-
maximal inhibition was observed (IC50 values) by ﬁtting the observed
neutralization to the expression 1/(1 + (IC50/x)^n), where x is the antibody
concentration and n is the Hill coefﬁcient.
Surface Plasmon Resonance. A Biacore T100 (GE Healthcare) with the T200
sensitivity enhancement was used to evaluate the interactions of antibodies
with gp140. Approximately 200, 750, and 2,500 response units (RUs) of YU2
gp140 were covalently immobilized on three ﬂow cells of a CM5 biosensor
chip, using standard primary amine coupling chemistry (Biacore manual).
Concentration series of Abs were injected at room temperature in 10 mM
Hepes with 150 mM NaCl, 3 mM EDTA, and 0.05% surfactant P20 at pH 7.4.
Equilibrium dissociation constants (Kds) were determined from kinetic con-
stants derived from sensorgram data, using simultaneous ﬁtting to the
association and dissociation phases of the interaction to a 1:1 binding model.
Because the injected proteins (the Abs) are capable of bivalent binding to
the immobilized gp140, this model produces apparent Kds that implicitly
include the avidity effects.
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